Poster Presentations: Wednesday, October 26, 2011 |

Risk-Benefit Tradeoffs in Lung Volume Reduction Surgery as a Bridge to Lung Transplantation for End-Stage Emphysema FREE TO VIEW

Norihisa Shigemura, MD; Sebastien Gilbert, MD; Jay Bhama, MD; Aditya Bansal, MD; Pramod Bonde, MD; Christian Bermudez, MD; Cynthia Gries, MD; Maria Crespo, MD; Bruce Johnson, MD; Joseph Pilewski, MD; James Luketich, MD; Yoshiya Toyoda, MD
Chest. 2011;140(4_MeetingAbstracts):668A. doi:10.1378/chest.1118056
Text Size: A A A
Published online


PURPOSE: When patients choose lung volume reduction surgery (LVRS) as a bridge to lung transplantation (LTx), they accept an increased risk of both LVRS-related and additional morbidity associated with LTx after LVRS in exchange for bridging the time to LTx. This study evaluates the risk-benefit tradeoffs in LVRS as a bridge to LTx for end-stage emphysema in a large-volume lung transplant center in the US.

METHODS: Twenty-five patients out of 177 patients who underwent LTx for end-stage emphysema had prior LVRS between 2002 and 2009 (LVRS group). We compared in-hospital morbidity, mid-term graft quality and long-term outcomes of LVRS group patients to a matched cohort (age-, gender-, procedure-, and transplant time-matched) to assess the possible added post-transplant morbidity and mortality.

RESULTS: LVRS group had 22 bilateral and 3 unilateral procedures and their subsequent LTx was performed 22.9±15.9 months (median, 25.5 months; range, 14 to 62 months). Postoperative respiratory complications and renal dysfunction requiring dialysis were higher in LVRS group whereas long-term survival was not significantly different (5-year survival, 59.7% in LVRS group versus 66.2%). Pulmonary functional improvement 6 months after LTx was significantly worse in LVRS group in view of FEV1 increase (22.3% vs. 54.2%, p<0.05). LVRS group had a higher incidence of primary graft dysfunction following LTx. Multivariate analysis showed CPB usage and pulmonary hypertension being the significant predictors for adverse early outcomes (p<0.05). Notably, there was a significantly higher 30-day mortality following LTx in the patients who developed greater than mild pulmonary hypertension (transpulmonary gradient pressure above 30 mmHg) after LVRS.

CONCLUSIONS: LVRS can bridge the time to transplantation in appropriately selected patients without significantly increasing post-transplant morbidity or mortality; however, LVRS can yield additional morbidity associated with LTx and it should be noted that high-risk patients exist in prior LVRS patients who result in higher mortality following LTx.

CLINICAL IMPLICATIONS: In very selected candidates, LVRS can be beneficial as either an alternative or a bridge to lung transplant for end-stage emphysema; however, our data suggest that patients who develop significant pulmonary hypertension after LVRS should be considered as high-risk candidates for subsequent lung transplantation.

DISCLOSURE: The following authors have nothing to disclose: Norihisa Shigemura, Sebastien Gilbert, Jay Bhama, Aditya Bansal, Pramod Bonde, Christian Bermudez, Cynthia Gries, Maria Crespo, Bruce Johnson, Joseph Pilewski, James Luketich, Yoshiya Toyoda

No Product/Research Disclosure Information

09:00 AM - 10:00 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543